Supplemental Material

Supplemental Table 1. Adjusted clinical outcome analysis of proBNP with BMI as ordinal variable.

	proBNP (>125 pg/mL)		Log transformed proBNP	
Model 1 (age, sex, race, BMI, hypertension, CAD, DM, smoking, CKD)				
	OR (95% CI)	**P-Value**	**OR (95% CI)**	**P-Value**
Death (n=1059)*	2.8 (1.6-4.8)	<0.0001	2.1 (1.6-2.7)	<0.0001
New HF (n=957)	2.8 (1.2-6.2)	0.013	3.1 (2.0-4.6)	<0.0001
Ventilator Need (n=1059)	3.3 (2.2-4.9)	<0.0001	2.0 (1.6-2.5)	<0.0001
	β (95% CI)	**P-Value**	**β (95% CI)**	**P-Value**
Length of Stay (n=1059)	4.7 (2.6-6.7)	<0.0001	2.7 (1.5-4.0)	<0.0001
ICU Duration (n=1059)	2.5 (0.9-4.0)	0.002	1.4 (0.5-2.4)	0.003
Model 2 (Model 1 + troponin I)				
	OR (95% CI)	**P-Value**	**OR (95% CI)**	**P-Value**
Death (n=636)	3.5 (1.6-7.5)	0.002	2.0 (1.4-3.0)	<0.001
New HF (n=578)	1.9 (0.8-4.6)	0.138	2.6 (1.6-4.3)	<0.0001
Ventilator Need (n=636)	3.6 (2.2-5.7)	<0.0001	2.2 (1.6-2.9)	<0.0001
	β (95% CI)	**P-Value**	**β (95% CI)**	**P-Value**
Length of Stay (n=636)	4.4 (1.5-7.4)	0.004	3.3 (1.4-5.2)	0.001
ICU Duration (n=636)	2.1 (-0.1-4.3)	0.062	1.9 (0.5-3.3)	0.008

*n indicates patients analyzed for indicated model and specified outcome. proBNP: pro-B-type natriuretic peptide, HF: heart failure, ICU: intensive-care unit, BMI: body mass index, CAD: coronary artery disease, DM: diabetes mellitus, CKD: chronic kidney disease. Logistic regression performed for categorical outcomes (Death, New HF and Ventilator Need), and regression coefficient is reported as an Odds Ratio (OR). Linear regression performed for continuous outcomes (Length of Stay, and ICU Duration), and regression coefficient is reported as β.

Supplemental Table 2. COVID-19 Registry patients with and without proBNP measurements.

Variable	proBNP measured (n=1232)	No proBNP measured (n=1426)	P-value
Sex (male)	657 (53.7%)	692 (48.5%)	0.008
Age (years)	62.9 (±17.5)	56.5 (±19.7)	<0.0001
Race/Ethnicity			0.72
White	343 (28.0%)	401 (28.1%)	
Black	440 (36.0%)	537 (37.7%)	
Hispanic	319 (26.1%)	361 (25.3%)	
Other	121 (9.9%)	127 (8.9%)	
Body mass index, kg/m^2	30.3 (±10.0)	29.2 (±7.7)	0.0068
Hypertension	702 (57.4%)	691 (48.5%)	<0.0001
Diabetes	387 (31.6%)	387 (27.1%)	0011
Coronary artery disease	110 (9.0%)	99 (6.9%)	0.051
Heart failure	130 (10.6%)	72 (5.1%)	<0.0001
Estimated GFR <60 cc/min (race adjusted)	435 (36.0%)	226 (29.7%)	0.01
History of smoking	222 (18.2%)	227 (15.9%)	0.127
Medications			
Aspirin	143 (11.7%)	135 (9.5%)	0.062
Statin	223 (18.2%)	186 (13.0%)	<0.0001
ACEi or ARB	197 (16.1%)	164 (11.5%)	0.001

Comparison of Demographics and Clinical Variables in patients with and without proBNP values measured. proBNP: pro- B-type natriuretic peptide, GFR: glomerular filtration rate, ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker